Clinical Pharmacokinetics

, Volume 56, Issue 5, pp 449–458 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL

  • Jennifer N. Clements
  • Tiffaney Threatt
  • Eileen Ward
  • Kayce M. Shealy
Review Article

Abstract

Concentrated insulin analogs have recently been approved and are available for clinical use in the management of diabetes mellitus. One new product is insulin glargine U-300 (Sanofi), a basal concentrated insulin of 300 U/mL. Several studies have been conducted and completed evaluating blood samples for the pharmacokinetics of insulin glargine U-300 and euglycemic clamp procedures for the pharmacodynamics. This concentrated insulin has a low within-day variability and high day-to-day reproducibility, allowing for a more constant and prolonged duration of action, compared with insulin glargine U-100 (100 U/mL). Insulin glargine U-300 is equally effective, when compared with insulin glargine U-100 for glycemic control in patients with type 1 and 2 diabetes mellitus. Insulin glargine U-300 has a similar efficacy profile to insulin glargine U-100 for glycemic control, yet with lower rates of nocturnal and severe hypoglycemia. Insulin glargine U-300 can be considered an acceptable basal insulin for patients with type 1 and 2 diabetes mellitus, and it has a potential role among patients who are naïve to insulin therapy or require titration of basal insulin. Titration of insulin glargine U-300 would result in less volume and a lower risk of hypoglycemia, compared with insulin glargine U-100. This article evaluates and summarizes the pharmacokinetics and pharmacodynamics of insulin glargine U-300, for patients with type 1 or 2 diabetes mellitus, and summarizes its application to clinical practice.

References

  1. 1.
    World Health Organization. Diabetes. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 31 May 2016.
  2. 2.
    Centers for Disease Control. Diabetes report card 2014. http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf. Accessed 31 May 2016.
  3. 3.
    Centers for Disease Control. Diabetes Public Health Resource: age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997–2011. http://www.cdc.gov/diabetes/statistics/meduse/fig2.htm. Accessed 23 Jun 2016.
  4. 4.
    Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95. doi:10.2337/db09-9028.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm. Endocr Pract. 2015;21:438–47.CrossRefPubMedGoogle Scholar
  7. 7.
    Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complicat. 2007;21(3):196–204.CrossRefPubMedGoogle Scholar
  8. 8.
    Frier DM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isphane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes. 2013;15(11):978–86.CrossRefGoogle Scholar
  9. 9.
    Riddle MC, Bolli GB, Zieman M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized, controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Yki-Jarvinen H, Bergenstal R, Zieman M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–94.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3A, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Riddle MC, Jarvinen HY, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17(9):835–42.Google Scholar
  14. 14.
    Yki-Jarvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (EDITION 2 randomised 12-month trial including 6-month extension). Diabetes Obes Metab. 2015;17(12):1142–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2, and 3 studies: glycaemic control and hypoglycaemia with insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859–67.Google Scholar
  16. 16.
    Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin:glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016;18:375–83.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Terachi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18:366–74.CrossRefGoogle Scholar
  18. 18.
    Toujeo (insulin glargine) [prescribing information]. Bridgewater: Sanofi-Aventis; 2015.Google Scholar
  19. 19.
    Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin. 2003;19:34–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 U/mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 U/mL−1. Diabetes Care. 2015;38:637–43.PubMedGoogle Scholar
  21. 21.
    Shiramoto M, Eto T, Fukuzaki A, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014;16:873–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure of insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35:2626–30.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Stella P, Aroda V, Charbonnel B, et al. Older people with type 2 diabetes: glycaemic control and hypoglycaemia risk with new insulin glargine 300 U/ml (Gla-300) [abstract 977]. Dianetologia. 2015;58(Suppl 1):S473.Google Scholar
  26. 26.
    Yale JF, Trescoli C, Cahn A, et al. Older people with T2DM: glycemic control and less hypoglycemia with insulin glargine 300 U/mL (Gla-300) vs Gla-100 a 1 year. Poster presented at: Advanced Technologies and Treatments for Diabetes; 3-6 Feb, 2016; Milan, Italy.Google Scholar
  27. 27.
    Twigg S, Escalada J, Grisoni ML, et al. Age, BMI and diabetes duration: effect on glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes (T2DM). Poster presented at Advanced Technologies and Treatments for Diabetes; 3-6 Feb, 2016; Milan, Italy.Google Scholar
  28. 28.
    Blair HA, Keating GM. Insulin glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76:363–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Bolli GB, DeVries JH. New long-acting insulin analogs: from clamp studies to clinical practice. Diabetes Care. 2015;38:541–3.PubMedGoogle Scholar
  30. 30.
    Bergenstal R, Bailey TS, Rodbard D, et al. Insulin glargine 300 U/mL vs 100 U/mL: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM) [abstract 39]. Diabetes Technol Ther. 2015;17(Suppl 1):A16–7.Google Scholar
  31. 31.
    Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhang Q, Rosenstock J, Gerrits C, et al. Is hypoglycaemia a modifiable patient risk in type 2 diabetes: a pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100 U/mL (Gla-100) trials [abstract 975]. Diabetologia. 2015;58(Suppl 1):S472.Google Scholar
  33. 33.
    Ritzel RA, Roussel R, Giaccari, et al. Patient-level meta-analysis of 1y phase 3a EDITION type 2 diabetes mellitus studies: glycaemic control and hypoglycemia with insulin glargine 300 U/ml (Gla-300) vs glargine 100 U/ml (Gla-100) [abstract 975]. Diabetologia. 2015;58(Suppl 1):S472.Google Scholar
  34. 34.
    Pohlmeier H, Klonoff DC, Berard L, et al. Ease of use of the new insulin glargine 300 U/mL SoloSTAR pen injector in insulin-naïve people with type 2 diabetes [abstract 1052P]. Diabetes. 2015;64(Suppl 1):A269–70.Google Scholar
  35. 35.
    Klonoff D, Nayberg I, Erbstein F, et al. Usability of the Gla-300 injection device compared with three other commercialized disposable insulin pens: results of an interview-based survey. J Diabetes Sci Technol. 2015;9(4):936–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252–7.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 2016;6:e009421.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Jennifer N. Clements
    • 1
  • Tiffaney Threatt
    • 1
  • Eileen Ward
    • 1
  • Kayce M. Shealy
    • 1
  1. 1.Department of Pharmacy PracticePresbyterian College School of PharmacyClintonUSA

Personalised recommendations